Key Highlights
- Third quarter Revenue rose 4% to USD 832.5 million, well above the USD 781.1 million estimate.
- EPS of USD 5.71 missed the USD 6.01 estimate and fell from USD 7.16 a year earlier.
- Tyvaso DPI sales grew 13% to USD 378.5 million, while Nebulized Tyvaso dropped 12% to USD 125.3 million.
- Research and development expense jumped 119% to USD 279.2 million, including USD 130.0 million of acquired development asset costs.
United Therapeutics (NASDAQ:UTHR) reported third quarter revenue of USD 832.5 million, up 4% from USD 799.5 million a year earlier and above the USD 781.1 million estimate. Diluted EPS of USD 5.71 trailed the USD 6.01 estimate and compared with USD 7.16 in the year-earlier quarter. Net Income fell to USD 258.6 million from USD 338.7 million.
Product Mix Shifts Within Tyvaso
Total Tyvaso net product sales rose 5% to USD 503.8 million, but the two formulations moved in opposite directions. Tyvaso DPI sales increased 13% to USD 378.5 million, helped by USD 43.9 million of higher Volume and a price increase, partly offset by larger gross-to-net deductions. Nebulized Tyvaso sales declined 12% to USD 125.3 million as U.S. volume fell USD 20.0 million.
Orenitram grew 11% to USD 145.0 million, and Unituxin rose 9% to USD 52.3 million. Remodulin slipped 3% to USD 122.0 million, and Adcirca fell 54% to USD 4.5 million. The company stated that competing therapies weighed on sales of Nebulized Tyvaso, Tyvaso DPI and Remodulin. U.S. revenue was USD 808.5 million, against USD 774.8 million a year ago.
Research Spending and Operating Costs
Research and development expense rose USD 151.7 million to USD 279.2 million. The largest driver was the other category, which rose to USD 130.0 million from USD 4.8 million and includes acquired in-process development costs tied to the Thymmune asset acquisition. External research spending rose 21% to USD 77.1 million and internal spending rose 20% to USD 61.0 million, with the company also citing manufactured organ and cardiopulmonary projects.
Selling, general and administrative expense fell 20% to USD 146.4 million because of a USD 66.5 million litigation accrual reversal, compared with a USD 0.8 million accrual a year earlier. Sales and Marketing expense increased 45% to USD 41.0 million. Operating Income was USD 307.8 million against USD 388.5 million, and income tax expense was USD 114.2 million versus USD 99.3 million.
Capital Position and Disclosures
Cash and equivalents were USD 1,188.9 million at September 30, with another USD 879.0 million in current marketable investments and USD 1,467.8 million in longer-term investments. Nine month Operating Cash Flow was USD 1,083.4 million, down from USD 1,215.0 million, while Capital expenditures rose to USD 389.5 million from USD 347.6 million. On October 21 the board approved a repurchase program of up to USD 2.0 billion through October 21, 2027.
Nine month revenue was USD 2,397.3 million, nearly flat with USD 2,392.5 million, because lower Nebulized Tyvaso and Remodulin sales offset growth in Tyvaso DPI and Orenitram. Nine month cost of sales rose 18% on higher inventory reserve expense, including USD 34.4 million tied to estimated losses under a commercial Supply agreement for Tyvaso DPI inventory.
Quarter in Numbers
Third quarter revenue of USD 832.5 million compares with USD 781.1 million estimated, while EPS of USD 5.71 compares with USD 6.01. Tyvaso DPI sales of USD 378.5 million sit against Nebulized Tyvaso at USD 125.3 million, and research expense of USD 279.2 million compares with USD 127.5 million a year ago. The USD 2.0 billion repurchase authorization compares with USD 1,188.9 million of cash on hand.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...